Active Biotech Stocks in Review – Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cytokinetics, Inc. (NASDAQ:CYTK), Galena BiopharmaInc (NASDAQ:GALE).
Houston, TX – April 12, 2013 — (Net PR News) – AnotherWinningTrade.com delivers quality trading ideas for the elite investor that has the financial wherewithal and market nimbleness to profit on small moves in a stock’s price. Become a member and you will be provided with real-time alerts intended to provide you with the opportunity to make profitable trades. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Stocks that are being watched this morning are: Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cytokinetics, Inc. (NASDAQ:CYTK), Galena BiopharmaInc (NASDAQ:GALE)
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) rose on Thursday after disclosing the pricing of an underwritten public offering of its common stock by existing shareholders, Beacon Company and Rosebay Medical Company L.P., including shares that were transferred to Beacon and Rosebay by Purdue Pharma L.P., an associated company of Beacon and Rosebay. The offering was priced at a public offering price of $40.00 per share.
How Should Investors Trade INFI Now? Don’t Trade INFI Until You Read This TREND ANALYSIS REPORT
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) gained +2.18% to close at $43.40 and its overall volume in the last trading session was 7.98 million shares, beating the average volume of 563,576. INFI hit the day high price of $43.57 and day low of $40.78.
The stock is trading with positive year-to-date performance of +24.00%. It has current ratio of 17.67 and its debt-to-equity ratio is 0.02. The company has total market cap of $2.07 billion.
Cytokinetics, Inc. (NASDAQ:CYTK) rose after it was the subject of a Seeking Alpha blog post.
Cytokinetics, Inc. (NASDAQ:CYTK) jumped +2.61% with the closing price of $1.18. The overall volume in the last trading session was 4.32 million shares. Its fifty two week range was $0.57-$1.28. The total market capitalization remained $168.05 million.
How Should Investors React To CYTK Now? Find Out In This TREND ANALYSIS REPORT
The stock is ahead of its 52 week low 107.02% and its last month price volatility remained 5.62%. Its beta coefficient was 1.80 with a target price of $3.70. In its share capital, the company has 146.46 million outstanding shares, while 131.84 million shares have been floated in the market.
It has insider ownership of 0.22% with its institutional ownership at 59.21%. Its current year earnings per share grew 48.19%.
Galena BiopharmaInc (NASDAQ:GALE) extended its 5-day gaining streak without any major news. The stock has been continuously closing higher since April 4, after a Seeking Alpha post titled “Galena Biopharma: Will Developments Continue In 2013?”.
Get A Free Report And Detailed Analysis On GALE CLICK HERE To Read
Galena BiopharmaInc (NASDAQ:GALE) shares went 6.52% up and closed at $2.45 in the last trading session. Its overall traded volume was 3.92 million shares. The stock’s opening price was $2.32, hitting the day high price of $2.46 and day low of $2.24.
GALE has earnings per share of -$0.63. The company has -77.54% returns on assets, -176.01% returns on equity and its return on investments is -113.29%.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.